Obesity, Fitness & Wellness Week

Tongjitang Chinese Medicines Company (NYSE: TCM) ("Tongjitang" or the "Company"), a vertically integrated and profitable specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine ("TCM") in China, announced that the Ministry of Science and Technology and the National Administration for the Protection of State Secrets of the People's Republic of China have granted the Company national trade secret status for its flagship product, Xianling Gubao ("XLGB").

The trade secret program in China protects intellectual property without publicly disclosing the detailed information involved in a patent application, such as manufacturing techniques or TCM formulae. Additionally, the state grants trade secret status to leading products demonstrating unique commercial value and brand value. Such products typically have a long history and proven efficacy in their respective markets, and presently in China there are approximately twenty TCM products with trade secret status.

Xiaochun Wang, Tongjitang's chief executive officer and chairman stated, "We are ecstatic to announce this significant milestone for our Company - which is a great testament to our leadership in the modernized TCM market. We are one of only a handful of modernized TCM providers to earn this honor and we are very pleased with the benefits we'll receive, such as manufacturing exclusivity and pricing protection. We also expect that new product developments, such as our next generation XLGB product, should receive expedited treatment from China's State Food & Drug Administration ("SFDA") when the time comes."